Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203177 · ClinicalTrials.gov registry record · Phase 3
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
NCT00203177 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 254 participants.
The verdict
NCT00203177, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
Study Summary
Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
Interventions
- DRUG rasagiline mesylate
- DRUG rasagiline mesylate 1.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2001-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203177
The ClinicalTrials.gov registry entry for NCT00203177 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rasagiline mesylate is the first listed.
NCT00203177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203177 about?
NCT00203177 is a clinical study titled "Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.". Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
What is the current status of trial NCT00203177?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2001-10.
What interventions are being tested in trial NCT00203177?
The interventions under investigation include: rasagiline mesylate (DRUG), rasagiline mesylate 1.0 mg (DRUG).
Who is sponsoring clinical trial NCT00203177?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.